Aeras links with new Chinese partner for TB vaccines
This article was originally published in Scrip
China has been fighting tuberculosis (TB) for decades and is increasingly burdened by the multidrug-resistant form of the mycobacterial infection, which causes nearly 120,000 cases each year or about 25% of the world's total. If no effective treatment is developed, the country will need to spend CNY99 billion ($15.6 billion) to treat 710,000 multidrug-resistant TB patients in the period to 2020, estimates the Beijing-based Chinese Center for Disease Control and Prevention (CCDC).
You may also be interested in...
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
The China Food and Drug Administration has released the final version of its biosimilars guideline1.